Who is Relmada?

Relmada Therapeutics, Inc.

Corporate profile
and investors’ information

Stock Information

Relmada Therapeutics is dedicated to reshaping the standard of care for central nervous system disorders.

Our lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in advanced clinical development for the treatment of major depressive disorder (MDD).

Data from the Phase 2 trial with REL-1017 suggest rapid, robust, and sustained antidepressant effects with statistically significant improvements as compared to placebo on all tested efficacy measures (Fava 2022). The Phase 2 study data also confirm the very favorable safety and tolerability profile of REL-1017 seen in Phase 1 studies (Bernstein 2019). The U.S. Food and Drug Administration has granted Fast Track designations to REL-1017 for the treatment of MDD. The Phase 3 Reliance clinical trial program is underway with Reliance II and Reliance OLS ongoing and an expected initiation of additional clinical evaluations.

Event - Mar 11 – Mar 13, 2024

Leerink Partners Global Biopharma Conference